Skip to main content

Advertisement

SpringerLink
Log in

Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

An Erratum to this article was published on 30 October 2015

Abstract

Purpose

The purpose of this study was to assess the efficacy of tolvaptan, a vasopressin V2 receptor agonist, for the management of postoperative surgical fluid retention after heart valve surgery.

Methods

This was a prospective observational study of 64 patients with heart valve disease who underwent valve surgery between 2013 and 2014. Those in the tolvaptan group received tolvaptan in addition to conventional diuretic therapy. The results were compared to the results of 55 patients who underwent heart valve surgery between 2007 and 2010 and received conventional postoperative diuretics alone.

Results

The time to return to the preoperative BW was significantly shorter in the patients who received tolvaptan (6.1 ± 3.8 vs. 8.7 ± 6.7 days, p < 0.05), while the level of sodium was significantly decreased in the patients who received conventional diuretics. The degree of increase in the creatinine level tended to be smaller in the tolvaptan group. The response to tolvaptan was related to the postoperative degree of BW increase and the preoperative creatinine level.

Conclusions

Tolvaptan was effective in treating fluid retention during the early postoperative stage in cardiac surgery patients, without increased renal failure or abnormal electrolyte levels. This new type of diuretic therapy may be a suitable option for postoperative fluid management in patients undergoing cardiac surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Gandhi A, Husain M, Salhiyyah K, Raja SG. Does perioperative furosemide usage reduce the need for renal replacement therapy in cardiac surgery patients? Interact CardioVasc Thorac Surg. 2012;15:750–5.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Sirivella S, Gielchinsky I, Parsonnet V. Mannitol, furosemide, and dopamine infusion in postoperative renal failure complicating cardiac surgery. Ann Thorac Surg. 2000;69:501–6.

    Article  CAS  PubMed  Google Scholar 

  3. Sezai A, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S, et al. Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose HANP Infusion Therapy during cardiac surgery) trial for CKD. J Am Coll Cardiol. 2011;58:897–903.

    Article  CAS  PubMed  Google Scholar 

  4. Sica D, Oren RM, Gottwald MD. Mills RM; Scios 351 Investigators. Natriuretic and neurohormonal responses to nesiritide, furosemide, and combined nesiritide and furosemide in patients with stable systolic dysfunction. Clin Cardiol. 2010;33:330–6.

    Article  PubMed  Google Scholar 

  5. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Hata N, Seino Y, Tsutamoto T, Hiramitsu S, Kaneko N, Yoshikawa T, et al. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J. 2008;72:1787–93.

    Article  CAS  PubMed  Google Scholar 

  7. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860–7.

    CAS  PubMed  Google Scholar 

  8. Miyazaki T, Yamamura Y, Onogawa T, Nakamura S, Kinoshita S, Nakayama S, et al. Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia. Endocrinology. 2005;146:3037–43.

    Article  CAS  PubMed  Google Scholar 

  9. Gheorghiade M, Gattis WA, O’Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–71.

    Article  CAS  PubMed  Google Scholar 

  10. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297:1319–31.

    Article  CAS  PubMed  Google Scholar 

  11. Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52:1540–5.

    Article  CAS  PubMed  Google Scholar 

  12. Matsuzaki M, Hori M, Izumi T, Fukunami M, Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011;25(Suppl 1):S33–45.

    Article  PubMed  Google Scholar 

  13. Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, et al. Acute heart failure volume control multicenter randomized (AVCMA) trial: comparison of tolvaptan and carperitide. J Clin Pharmacol. 2013;53:1277–85.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients—association between non-responders and chronic kidney disease. Circ J. 2013;77:397–404.

    Article  CAS  PubMed  Google Scholar 

  15. Kinugawa K, Sato N, Inomata T, Shimakawa T, Iwatake N, Mizuguchi K. Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circ J. 2014;78:844–52.

    Article  CAS  PubMed  Google Scholar 

  16. Hendren WG, Higgins TL. Immediate postoperative care of the cardiac surgical patient. Semin Thorac Cardiovasc Surg. 1991;3:3–12.

    CAS  PubMed  Google Scholar 

  17. Lim E, Ali ZA, Attaran R, Cooper G. Evaluating routine diuretics after coronary surgery: a prospective randomized controlled trial. Ann Thorac Surg. 2002;73:153–5.

    Article  PubMed  Google Scholar 

  18. Lassnigg A, Donner E, Grubhofer G, Presterl E, Druml W, Hiesmayr M. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol. 2000;11:97–104.

    CAS  PubMed  Google Scholar 

  19. Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med. 1991;114:886–94.

    Article  CAS  PubMed  Google Scholar 

  20. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Tsukui H. Yamazaki K Contemporary strategy for aortic valve stenosis in octogenarians. Surg Today. 2014;44:992–1003.

    Article  PubMed  Google Scholar 

  22. Abramow M. Cogan E Clinical aspects and pathophysiology of diuretic-induced hyponatremia. Adv Nephrol Necker Hosp. 1984;13:1–28.

    CAS  PubMed  Google Scholar 

  23. Shirakabe A, Hata N, Yamamoto M, Kobayashi N, Shinada T, Tomita K, et al. Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure. Circ J. 2014;78:911–21.

    Article  CAS  PubMed  Google Scholar 

  24. Hobson CE, Yavas S, Segal MS, Schold JD, Tribble CG, Layon AJ, et al. Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery. Circulation. 2009;119:2444–53.

    Article  PubMed  Google Scholar 

  25. Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O’Connor CM, Califf RM, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007;9:1064–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Cardiovasc Drugs Ther. 2011;25(Suppl 1):S67–76.

    Article  PubMed  Google Scholar 

  27. Imamura T, Kinugawa K, Fujino T, Inaba T, Maki H, Hatano M, et al. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J. 2014;78:2240–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, 2-2, Yamada-Oka, Suita, Osaka, 565-0871, Japan

    Hiroyuki Nishi, Koichi Toda, Shigeru Miyagawa, Yasushi Yoshikawa, Satsuki Fukushima, Masashi Kawamura, Daisuke Yoshioka, Tetsuya Saito, Takayoshi Ueno, Toru Kuratani & Yoshiki Sawa

Authors
  1. Hiroyuki Nishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Koichi Toda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shigeru Miyagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasushi Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Satsuki Fukushima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masashi Kawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Daisuke Yoshioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tetsuya Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takayoshi Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Toru Kuratani
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yoshiki Sawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshiki Sawa.

Ethics declarations

Funding

There was no funding for this trial.

Disclosures

H.N. has a potential conflict of interest with Otsuka Pharmaceutical, which consists of lecture fees and travel expenses.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nishi, H., Toda, K., Miyagawa, S. et al. Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial. Surg Today 45, 1542–1551 (2015). https://doi.org/10.1007/s00595-015-1251-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-015-1251-y

Keywords

Search

Navigation